Introduction to Gilead Sciences and Benchling Partnership
Gilead Sciences, a renowned biopharmaceutical company dedicated to medical breakthroughs, partnered with Benchling to enhance large molecule bioprocess development. With a focus on novel therapies for life-threatening diseases, Gilead sought to bolster scientist productivity, collaboration, and data insights to elevate efficiency and predictability in their development processes.
Challenges Faced by Gilead Sciences
Gilead encountered challenges due to siloed project data, hindering information flow across teams. Managing multiple systems and databases through disparate tools led to data silos and manual handoffs that bottlenecked processes. Additionally, aggregating data for analysis was time-consuming, impeding data-driven decision-making.
Transformational Outcomes with Benchling Implementation
Implementing Benchling resolved Gilead's data unification issues by creating a centralized platform for improved collaboration. The platform enabled seamless end-to-end sample traceability and data aggregation across different teams. Standardized data capture and an intuitive interface enhanced scientist productivity, allowing for automated status tracking and quick access to analytical results.
Enabling Data-Driven Decision Making
Benchling facilitated clearer insights for Gilead's scientists by simplifying data aggregation and trend analysis. The platform empowered the Biologics team to monitor processes effectively, identifying deviations and progress within workflows. Utilizing Benchling's audit trails and review processes, Gilead could make data-driven decisions to optimize parameters and protocols.
Conclusion: Benchling's Impact on Gilead Sciences
The collaboration between Gilead Sciences and Benchling resulted in substantial improvements, including enhanced data sharing, reduced data capture time, and increased study review efficiency. By leveraging Benchling's capabilities, Gilead advanced its large molecule bioprocess development, setting a new standard for productivity and innovation in the biopharmaceutical industry.